Research Grants

GARY ASTON-JONES
Neurosciences. Role of Locus Coeruleus in Decision Outcome, $429,000 from Princeton University, September 2009 through August.
Gene Transfer Into Selected Brain Neurons In Vivo, $181,395 from National Institute on Drug Abuse, January through December.

CARL ATKINSON
Division of Basic Sciences. The Role of Complement in the Pathogenesis of Emphysema, $368,750 from National Heart, Lung and Blood Institute, March through February 2011.

MARCY B. BOLSTER
Medicine. Phase 3, Randomized, Double-Blind Study of the Efficacy and Safety of 2 Doses of CP-690,550 Compared to Methotrexate in Methotrexate-Naive Patients with Rheumatoid Arthritis, $89,790 from  Icon Clinical Research Inc., March through June 2013.

FREDRIC R. BOOCKFOR
Cell Biology and Anatomy. Prolactin Gene Expression Dynamics and Mammotrope Function- Administrative Supplement, $98,751 from National Institute of Diabetes and Digestive and Kidney Diseases, March through February 2011.

CHARLES F. BRATTON
Surgery. A Facilitated Access Program to Provide Everolimus (RAD) for Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation, $3,900 from Novartis Corp., February 2004 through June.

MILOS BUDISAVLJEVIC
Medicine. Detection and Characteri-zation of Glomerulonephritis Associated Proteins, $159,000 from  Dialysis Clinics Inc., January 2007 through December 2012.

MARIA G. BUSE
Medicine. Factors That Modify Insulin Action, $315,414 from National Institute of Diabetes and Digestive and Kidney Diseases, March through February 2011.

MATTHEW J. CARPENTER
Psychiatry and Behavioral Sciences. A Pilot RCT to Examine a Potentially Reduced Exposure Tobacco Product, $40,000 from Prevent Cancer Foundation, January through January 2011.

KENNETH CHAVIN
Surgery. A 12-Month, Multi-Center, Randomized, Open-Label, Non-Inferiority Study of Efficacy and Safety Comparing Concentration-Controlled Everolimus with Low Dose Tacrolimus to Cellcept with Standard Dose Tacrolimus in De Novo Renal Transplant Recipients, $334,072 from Novartis Corp., September 2009 through May 2013.

SONYA D. COAXUM
Medicine. Targeting of G Protein Coupled 5-HT1A Receptors, $30,000 from Dialysis Clinics Inc., March 2009 through December 2012.

LAWRENCE W. COMERFORD
Medicine. A Phase, 2/3 Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis, $99,813 from Centocor Inc., January through February 2011.

LUCIANO J. COSTA
Medicine. Phase 2, Trial of Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia (CLL) Patients Previously Exposed To Rituximab, $130,640 from GlaxoSmithKline, January through January 2015.

CRAIG CROSSON
Ophthalmology. Adenosine Agonists: Potential Anti-Glaucoma Agents, $373,045 from National Eye Institute, March through February 2011.

CHRISTOPHER DAVIES
Division of Basic Sciences. Molecular Targets in Peptidoglycan Synthesis, $289,080 from National Institute of General Medicine Sciences, March through February 2011.

ANTHONY DUNBAR
Public Safety. Bulletproof Vest Partnership Grant, $2,123 from S.C. Department of Public Safety, January through December.

SCOTT T. EBLEN
Division of Basic Sciences. Regulation of Ovarian Cancer Multidrug Resistance by MAP Kinases, $305,274 from National Cancer Institute, March through January 2011.

BRENT M. EGAN
Medicine. MUSC Hypertension Initiative of SC, $37,000 from SC Department of Health and Environmental Control, March through March 2011.

DILANTHA B. ELLEGALA
Neurosciences. Clot Lysis: Evaluating Accelerated Resolution of IVH Phase III (CLEAR III), $78,563 from Johns Hopkins University, July 2009 through June.

CHRISTOPHER R. GAULT
Medicine. The Role of Sphingosine Kinase 1 in Ras-Initiated Lung Carcinogenesis, $37,387 from National Heart, Lung and Blood Institute, February through January 2011.

LEONIE GORDON
Radiology. The ASPECT Trial: A Phase III, Randomized, Double-Blind Crossover Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI), $179,375 from PPD Development, November 2009 through January 2011.

GARY F. HEADDEN
Medicine. Copeptin Helps in the Early Detection of Patients with Acute Myocardial Infarction (CHOPIN), $117,500 from Brahms AG, January through January 2011.

SUSAN D. HOFFIUS
Library Science and Informatics. Express Library Digitization Award, $5,000 from Univerity of Maryland, March through February 2011.

JOSHUA D. HORNIG
SHAUN A. NGUYEN (Co-PI)
Otolaryngology. A Prospective, Blinded, Randomized, Controlled Trial Comparing Wound Drainage and Post-Operative Complications with and without the Use of EVICEL Fibrin Sealant in Thyroidectomy, $100,000 from Ethicon, March through February 2012.

MICHELLE PHILLIPS HUDSPETH
Pediatrics. A 5-year, Prospective, Non-Interventional, Multi-Center Registry in Sickle Cell Disease Patients, $68,500 from Novartis Corp., December 2009 through December 2017.

MARK S. KINDY
Neurosciences. Lowcountry Partnership for Biomedical Innovation, $72,583 from College of Charleston, March through February 2011.

RAYNA KNEUPER-HALL
RITA M. KRAMER (Co-PI)
Medicine. A Phase III, Clinical, Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer, $74,000 from National Surgical Adjuvant Breast and Bowel Project, October 2009 through September 2014.

ARCH MAINOUS
Family Medicine. Bipolar Midpoint Analysis - Using an EMR-Based Intervention to Improve Screening and Diagnosis of Bipolar Disorder in Primary Care, $10,000 from Delaware Valley Outcomes Research, February through June.